BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 38614068)

  • 21. Efficacy and toxicity of drugs targeting KRAS
    Luo W; Zhu J; Zhang W; Yu A; Zhou W; Xu K
    Expert Rev Anticancer Ther; 2023; 23(12):1295-1303. PubMed ID: 37950424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital].
    Bessy C; Blin T; Pichon E; Marchand-Adam S; Carmier D
    Rev Mal Respir; 2023 Jan; 40(1):17-23. PubMed ID: 36566134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of current immune checkpoint inhibitors in non-small cell lung cancer.
    Abdayem P; Planchard D
    Expert Opin Drug Saf; 2021 Jun; 20(6):651-667. PubMed ID: 33393387
    [No Abstract]   [Full Text] [Related]  

  • 25. Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib.
    Zhang J; Johnson M; Barve M; Bazhenova L; McCarthy M; Schwartz R; Horvath-Walsh E; Velastegui K; Qian C; Spira A
    Oncologist; 2023 Apr; 28(4):287-296. PubMed ID: 36892150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
    Mausey N; Halford Z
    Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.
    Strohbehn GW; Sankar K; Qin A; Kalemkerian GP
    Expert Opin Pharmacother; 2022 Oct; 23(14):1569-1575. PubMed ID: 36217844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Lin LL; Lin GF; Luo Q; Chen XQ
    Int Immunopharmacol; 2019 Dec; 77():105975. PubMed ID: 31704288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
    Chour A; Basse C; Lebossé F; Bonte PE; Girard N; Duruisseaux M
    Lung Cancer; 2024 May; 191():107789. PubMed ID: 38614068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sotorasib: First Approval.
    Blair HA
    Drugs; 2021 Sep; 81(13):1573-1579. PubMed ID: 34357500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
    Lee A
    Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
    Luo W; Wang Z; Tian P; Li W
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 2.